[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-334772-en":59,"doc-seo-334772-105":81},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":4},334772,4810365810221,"Aurora","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor","Solid cancers commonly establish an immunosuppressive tumor microenvironment (TME) largely supported by myeloid cells with anti-inflammatory, pro-tumor properties, which can limit the impact of cancer immunotherapies. To overcome these barriers, an adoptive cell therapy was developed using myeloid cells engineered to express a CAR-like immune receptor (CARIR) that targets the checkpoint pathway. The CARIR extracellular region derives from PD-1, with intracellular signaling from CD40 and/or CD3z, and was tested using in vitro co-culture and flow cytometry phagocytosis assays as well as an immune-competent syngeneic tumor mouse model.","TYPE Original Research PUBLISHED 25 April 2024  \nDOI 10.3389/fimmu.2024.1380065  \nOPEN ACCESS  \nEDITED BY Yao Wang,  \nChinese PLA General Hospital, China  \nREVIEWED BY Arpad Szoor,  \nUniversity of Debrecen, Hungary Jacob T. Jackson,  \nThe University of Melbourne, Australia  \n*CORRESPONDENCE Ai-Hong Zhang  \n [ahzhang0501@gmail.com](ahzhang0501@gmail.com)[ ](ahzhang0501@gmail.com)Peter Andersen  \n [Pander31@jhmi.edu](Pander31@jhmi.edu)  \n†These authors have contributed equally to this work  \n‡These authors have contributed equally to this work and share last authorship  \nRECEIVED 31 January 2024  \nACCEPTED 09 April 2024  \nPUBLISHED 25 April 2024  \nCITATION  \nMyers Chen K, Grun D, Gautier B, Venkatesha S, Maddox M, Zhang AH and Andersen P (2024) Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor.  \nFront. Immunol. 15:1380065 .  \ndoi: 10.3389/fimmu.2024.1380065  \nCOPYRIGHT  \n© 2024 Myers Chen, Grun, Gautier, Venkatesha, Maddox, Zhang and Andersen.  \nThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTargeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor  \nKayla Myers Chen 1†, Daniel Grun 1†, Brian Gautier 1, Shivaprasad Venkatesha 1, Michael Maddox 1,  \nAi-Hong Zhang 1*‡ and Peter Andersen 1,2*‡  \n1Vita Therapeutics, Baltimore, MD, United States, 2 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States  \nIntroduction: Solid cancers Myeloid cells are prevalent in solid cancers, but they frequently exhibit an anti-inﬂammatory pro-tumor phenotype that contribute to the immunosuppressive tumor microenvironment (TME), which hinders the effectiveness of cancer immunotherapies. Myeloid cells’ natural ability of tumor trafﬁcking makes engineered myeloid cell therapy an intriguing approach to tackle the challenges posed by solid cancers, including tumor inﬁltration, tumor cell heterogenicity and the immunosuppressive TME. One such engineering approach is to target the checkpoint molecule PD-L1, which is often upregulated by solid cancers to evade immune responses.  \nMethod: Here we devised an adoptive cell therapy strategy based on myeloid cells expressing a Chimeric Antigen Receptor (CAR)-like immune receptor (CARIR) . The extracellular domain of CARIR is derived from the natural inhibitory receptor PD-1, while the intracellular domain(s) are derived from CD40 and/or CD3z. To assess the efﬁcacy of CARIR-engineered myeloid cells, we conducted proof-of-principle experiments using co-culture and ﬂow cytometry-based phagocytosis assays in vitro. Additionally, we employed a fully immune-competent syngeneic tumor mouse model to evaluate the strategy ’s effectiveness in vivo.  \nResult: Co-culturing CARIR-expressing human monocytic THP-1 cells with PDL1 expressing target cells lead to upregulation of the costimulatory molecule CD86 along with expression of proinﬂammatory cytokines TNF-1a and IL-1b. Moreover, CARIR expression signiﬁcantly enhanced phagocytosis of multiple PD-L1 expressing cancer cell lines in vitro. Similar outcomes were observed with CARIR-expressing human primary macrophages. In experiments conducted in syngeneic BALB/c mice bearing 4T1 mammary tumors, infusing murine myeloid cells that express a murine version of CARIR signiﬁcantly slowed tumor growth and prolonged survival.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nConclusion: Taken together, these results demonstrate that adoptive transfer of PD-1 CARIR-engineered myeloid cells represents a promising strategy for treating PD-L1 positive solid can","cbCailI67NU4UeLk","https://ap.wps.com/l/cbCailI67NU4UeLk","pdf",2680884,11,"English","en",105,"# Introduction\n## Rationale and therapeutic concept\n# Method\n## CARIR design and experimental setup\n# Result\n## In vitro activation and phagocytosis\n## In vivo tumor control and survival\n# Conclusion\n## Clinical relevance for PD-L1 positive solid cancers","[{\"question\":\"Why target PD-L1 in solid cancer using engineered myeloid cells?\",\"answer\":\"Solid cancers often upregulate PD-L1 to evade immune responses, and myeloid cells in the TME frequently support an immunosuppressive, pro-tumor phenotype. Targeting PD-L1 with engineered myeloid cells aims to counter these mechanisms and improve immunotherapy effectiveness.\"},{\"question\":\"How was the CAR-like immune receptor (CARIR) constructed?\",\"answer\":\"The CARIR extracellular domain was derived from PD-1, while the intracellular domain(s) were derived from CD40 and/or CD3z. This design was used to create PD-L1-targeting signaling in myeloid cells.\"},{\"question\":\"What were the key experimental findings in vitro and in vivo?\",\"answer\":\"In vitro, co-culturing CARIR-expressing THP-1 cells with PD-L1-expressing targets increased CD86 and pro-inflammatory cytokines, and CARIR expression enhanced phagocytosis across multiple PD-L1-positive cancer cell lines. In syngeneic BALB/c mice bearing 4T1 tumors, infusing murine CARIR-expressing myeloid cells slowed tumor growth and prolonged survival.\"}]","Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor | PDF",1790008315,28,{"code":4,"msg":82,"data":83},"ok",{"site_id":75,"language":74,"slug":84,"title":65,"keywords":85,"description":66,"schema_data":86,"social_meta":140,"head_meta":142,"extra_data":144,"updated_unix":145},"targeting-pd-l1-in-solid-cancer-with-myeloid-cells-expressing-a-car-like-immune-receptor","",{"@graph":87,"@context":139},[88,102,122],{"@type":89,"itemListElement":90},"BreadcrumbList",[91,95,97,100],{"item":92,"name":93,"@type":94,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":96,"name":9,"@type":94,"position":14},"https://docshare.wps.com/document/",{"item":98,"name":40,"@type":94,"position":99},"https://docshare.wps.com/document/research-report/",3,{"item":101,"name":65,"@type":94,"position":19},"https://docshare.wps.com/document/targeting-pd-l1-in-solid-cancer-with-myeloid-cells-expressing-a-car-like-immune-receptor/334772/",{"url":101,"name":65,"@type":103,"image":104,"author":109,"headline":65,"publisher":111,"fileFormat":114,"inLanguage":74,"description":66,"dateModified":115,"datePublished":116,"encodingFormat":114,"isAccessibleForFree":117,"interactionStatistic":118},"DigitalDocument",{"url":105,"@type":106,"width":107,"height":108},"https://docshare.wps.com/thumbnails/targeting-pd-l1-in-solid-cancer-with-myeloid-cells-expressing-a-car-like-immune-receptor/334772.png","ImageObject",300,407,{"name":63,"@type":110},"Person",{"url":92,"name":112,"@type":113},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":119,"interactionType":120,"userInteractionCount":19},"InteractionCounter",{"@type":121},"ViewAction",{"@type":123,"mainEntity":124},"FAQPage",[125,131,135],{"name":126,"@type":127,"acceptedAnswer":128},"Why target PD-L1 in solid cancer using engineered myeloid cells?","Question",{"text":129,"@type":130},"Solid cancers often upregulate PD-L1 to evade immune responses, and myeloid cells in the TME frequently support an immunosuppressive, pro-tumor phenotype. Targeting PD-L1 with engineered myeloid cells aims to counter these mechanisms and improve immunotherapy effectiveness.","Answer",{"name":132,"@type":127,"acceptedAnswer":133},"How was the CAR-like immune receptor (CARIR) constructed?",{"text":134,"@type":130},"The CARIR extracellular domain was derived from PD-1, while the intracellular domain(s) were derived from CD40 and/or CD3z. This design was used to create PD-L1-targeting signaling in myeloid cells.",{"name":136,"@type":127,"acceptedAnswer":137},"What were the key experimental findings in vitro and in vivo?",{"text":138,"@type":130},"In vitro, co-culturing CARIR-expressing THP-1 cells with PD-L1-expressing targets increased CD86 and pro-inflammatory cytokines, and CARIR expression enhanced phagocytosis across multiple PD-L1-positive cancer cell lines. In syngeneic BALB/c mice bearing 4T1 tumors, infusing murine CARIR-expressing myeloid cells slowed tumor growth and prolonged survival.","https://schema.org",{"og:url":101,"og:type":141,"og:title":65,"og:site_name":112,"og:description":66},"article",{"robots":143,"canonical":101},"index,follow",{"doc_id":61,"site_id":75},1790867805]